Faeth Therapeutics, Inc. Accretion Expense
Faeth Therapeutics, Inc. (FTH) reported Accretion Expense of $1.58 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2022-03-15
- Faeth Therapeutics, Inc. accretion expense for the quarter ending 2020-12-31 was $0.00.
- Faeth Therapeutics, Inc. accretion expense for the quarter ending 2020-09-30 was $0.00.
- Faeth Therapeutics, Inc. accretion expense for the quarter ending 2020-06-30 was $0.00.
- Faeth Therapeutics, Inc. accretion expense for the quarter ending 2020-03-31 was $1.58M.
- Faeth Therapeutics, Inc. accretion expense for fiscal 2020 was $1.58M.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $1.58M 10-K · filed 2022-03-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $1.58M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.58M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $1.58M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |